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Genetic changes occurring in different stages of pre-cancer lesions reflect causal events
initiating and promoting the progression to cancer. Co-existing pre-cancerous lesions
including low- and high-grade squamous intraepithelial lesion (LGSIL and HGSIL), and adja-
cent “normal” cervical epithelium from six formalin-fixed paraffin-embedded samples were
selected. Tissues from these 18 samples were isolated using laser-capture microdissec-
tion, RNA was extracted and sequenced. RNA-sequencing generated 2.4 billion raw reads
in 18 samples, of which ~50.1% mapped to known and annotated genes in the human
genome. There were 40 genes up-regulated and 3 down-regulated (normal to LGSIL) in at
least one-third of the sample pairs (same direction and FDR p<0.05) including S100A7
and KLK6. Previous studies have shown that S110A7 and KLK7 are up-regulated in sev-
eral other cancers, whereas CCL18, CFTR, and SLC6A14, also differentially expressed in
two samples, are up-regulated specifically in cervical cancer.These differentially expressed
genes in normal to LGSIL progression were enriched in pathways related to epithelial cell
differentiation, keratinocyte differentiation, peptidase, and extracellular activities. In pro-
gression from LGSIL to HGSIL, two genes were up-regulated and five down-regulated in
at least two samples. Further investigations using co-existing samples, which account for
all internal confounders, will provide insights to better understand progression of cervical
pre-cancer.
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INTRODUCTION
Squamous cell carcinoma of the cervix results from a sequence
of well delineated non-invasive pre-cancer stages. Based on the
cytological findings of Bethesda Classification system (1), these
pre-cancer stages are classified as low-grade squamous intraepithe-
lial lesion (LGSIL), consisting of cytological atypia and histological
cervical intraepithelial lesion (CIN) 1, and high-grade squamous
intraepithelial lesion (HGSIL), consisting primarily of CIN 2–3
plus carcinoma in situ (2, 3). In 2014, it is estimated that 12,360
cases of invasive cervical cancer will occur in the United States;
however, 1.25 million women are expected to be diagnosed with
pre-cancer by a Papanicolaou (Pap) test (4). Similarly, ~600,000
cervical cancers are expected worldwide, with epidemic propor-
tions of pre-cancers, mostly undiagnosed (5). Studies of cervical
disease progression (6) suggest that lesions in ~60% of women
with LGSIL will spontaneously regress, another 20–30% will per-
sist unchanged, about 5–10% will progress to high-grade HGSIL,
and only 1% will develop invasive carcinoma (6, 7). The like-
lihood of HGSIL regression is 33%; progression to invasion is
>12% (6). Persistent high-risk HPV (HR-HPV) infection (8),
high-viral load (9), and integration of HPV DNA (10) are likely
markers or determinants of progression of pre-cancer lesions to
cervical cancer; however, host factors have not been thoroughly
studied. While genetic alterations in cancer are common, changes
found in different grades of pre-cancer lesions are more likely
to reflect causal events initiating and promoting the progression
to cancer, yet little is known about these genomic changes that
occur.
Some experts arguably consider that it is reasonable standard-
care to follow low-grade pre-cancer lesions and HPV infections
without active treatment. Since HPV infection and LGSIL are
diagnosed in epidemic proportions, novel biomarkers with higher
specificity for cervical lesions would improve cervical cancer
screening. Better early detection biomarkers would also greatly
assist in the stratification of patients for chemoprevention trials of
pre-neoplasia. Currently, there are no validated diagnostic or prog-
nostic biomarkers that identify LGSIL destined toward HGSIL or
cervical cancer. Since HGSIL are near-obligate precursors of cer-
vical cancer, it is standard clinical practice to use invasive surgical
interventions to reduce the burden of progression to cancer. The
detection of LGSIL that may progress to HGSIL and the prevention
of this progression is an important and suitable goal for non-
invasive medical intervention to reduce the incidence of cervical
cancer.
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Gene expression studies are quite sparse for HPV-related cervi-
cal dysplasia. Squamous cell carcinoma of the cervix results from a
sequence of well delineated non-invasive pre-cancer stages. Quan-
tifying the decisive physical changes, i.e., differential function and
expression of genes in the co-existing “normal” cervical epithe-
lium and neighboring pre-cancerous lesions; low-grade squamous
intraepithelial lesions (LGSIL) and high-grade squamous intraep-
ithelial lesions (HGSIL) will elucidate when, where, and to what
extent genomic variations facilitate development and progres-
sion of pre-cancer. Since LGSIL and HGSIL lesions are generally
related when they co-occur, these types of samples provide an
opportunity to assess morphologic progression with regard to
space and time, while controlling for internal confounders (11).
Specifically, RNA sequencing (RNA-seq) can examine expres-
sion patterns of genes from formalin-fixed paraffin-embedded
(FFPE) tissues, which can be used to study pre-cancer progres-
sion in co-existing LGSIL and HGSIL tissues (12). In the current
study, we utilized laser-capture microdissection to extract spe-
cific tissues from co-existing neoplastic stages (normal, LGSIL,
and HGSIL) on FFPE samples from six women who under-
went loop electrosurgical extraction procedures (LEEP), and per-
formed innovative RNA extraction and sequencing (RNA-seq)
technologies to enable comprehensive gene expression profil-
ing of selected cell types for comparison within and between
individuals.
MATERIALS AND METHODS
STUDY POPULATION AND PATIENT SAMPLE SELECTION
The patient samples were obtained from the University of Alabama
at Birmingham (UAB) Comprehensive Cancer Center (UAB-
CCC) tissue procurement shared facility (TPSF) where standard
protocols are followed to routinely collect cervical samples from
the UAB colposcopy clinic and preserve as FFPE tissues (13).
Since formalin fixation methodology, which affects nucleic acid
integrity, can vary among hospital laboratories, we used only
samples from women that received LEEP treatment at the UAB
colposcopy clinics during June 2010 to April 2012 for abnor-
mal cytology. A UAB pathologist prospectively reviewed cervical
tissue samples from ~850 women, aged 20–25 years old to con-
firm if they had a co-existing spectrum of normal and pre-cancer
LGSIL and HGSIL on the sample block (Figure 1). If co-existing
lesions (LGSIL and HGSIL) were found for LEEP treatments dur-
ing that period, women must have had HGSIL (CIN2/3) confirmed
biopsies within 6 months of their treatment. Samples with evi-
dence of immunosuppression or HIV infection were excluded
due to known differences in rates of cervical abnormalities and
pathogenesis (14, 15). Following these criteria, we identified 10
FFPE blocks from European American women (Figure S1 in
Supplementary Material) of whom 6 were similar in relation
to information on referral, cytology, demographic characteris-
tics, and subsequent histologic biopsy (Table 1) are used for the
study. Specific laboratory methods (Figure 1) were followed as
specified below. The study protocols using these samples con-
formed to human-experimentation guidelines set forth by the
United States Department of Health and Human Services and
was reviewed and approved by institutional review board (IRB)
at UAB.
FIGURE 1 | Schematic flow of the study design, sample selection,
experimental methodology, and analysis.
SLIDE PREPARATION
Formalin-fixed paraffin-embedded blocks from six participants
were used for slide preparation and microdissection. First, the
pathologist, an expert in gynecologic lesion analysis, identified
and marked 12 pre-cancerous lesions (LGSIL and HGSIL in each)
and 6 co-existing normal tissues, respectively, to ensure the correct
cell populations. Then, depending on the size of the tissues on the
block, two to six 10µm sections from the FFPE blocks were cut
using RNAse-free blades at each area identified by the patholo-
gist and mounted on the coated slide (Leica Microsystems, Buffalo
Grove, IL, USA). To prevent contamination, a new blade and a
different slide was prepared for each cell type (normal, LGSIL, and
HGSIL) and captured separately. The samples were heated in a
water bath (58°) for 2 min and the paraffin debris was carefully
scraped off. No staining of samples was performed since it can
further degrade RNA in FFPE tissues.
MICRODISSECTION METHOD
To reduce sample degradation, all laboratory procedures includ-
ing sample preparation, microdissection, and RNA extraction were
performed within a 24 h period. Microdissection of the 18 specific
tissues (adjacent normal, LGSIL, and HGSIL) from 6 participants
was performed to reduce possible contamination of different cell
types in heterogeneous tissue, which could mask the detection of
gene expression alterations in the cells of interest. Slide prepara-
tion, laser-capture microdissection (LCM), and RNA extraction
was conducted at LifeSpan Molecular Pathology Core Services lab
in Providence, Rhode Island. LCM was conducted using the Arc-
turus Veritas Laser-Capture Microdissection (Mountain View, CA,
USA) to isolate individual cell populations from distinct normal
and pre-cancer LGSIL and HGSIL cells, which were then placed
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Table 1 | Demographic and LEEP diagnosis information from study of cervical dysplasia FFPE co-existing HGSIL and LGSIL lesions.
Sample
ID number
Age Smoker HGSIL LEEP diagnosis ICD9
code
Keratinizing
dysplasia
Glandular
involvement or
extension
Loop
margins
Adjacent
normal sample
location
#109 25 No CIS of cervix uteri (includes all CIN3) 233.1 Yes Yes − HGSIL
#110 23 Yes CIS of cervix uteri (includes all CIN3) 233.1 No No − HGSIL
#111 24 Yes CIS of cervix uteri (includes all CIN3) 233.1 No No + –
#113 29 Yes Moderate dysplasia of cervix (CIN2) 622.12 No No + LGSIL
#115 25 Unknown Moderate dysplasia of cervix (CIN2) 622.12 Yes Yes + LGSIL
#116 23 Unknown CIS of cervix uteri (includes all CIN3) 233.1 No No − LGSIL
on CapSure HS LCM Caps using the UV capture laser protocols.
Adjacent stained slides were used as a roadmap to determine which
areas would be collected. The relatively low intensity of the laser
does not damage DNA, RNA, or proteins in the captured cells
(16). Approximately 10,000 cells were collected per tissue sam-
ple onto a single LCM cap. Each population of captured cells
was re-examined by microscopic visualization for confirmation,
and before and after images of each sample were taken (Figure
S1 in Supplementary Material) for additional confirmation by a
gynecologic pathologist specialized in cancers.
RNA EXTRACTION
Total RNA was extracted from all 18 microdissected tissues from
6 to 10 LCM using the Qiagen AllPrep DNA/RNA Micro Kit (Qia-
gen, CA, USA), according to the manufacturer’s instructions, with
extended proteinase K digestion. Prior to amplification, the quality
and level of degradation of the extracted RNA was assessed with
RIN (RNA integrity number) assigned by the Agilent 2100 Bioan-
alyzer instrument using the RNA 6000 Pico kit (Agilent Technolo-
gies, Santa Clara, CA, USA). All 18 samples were stored in nuclease-
free tubes and stored at−80°C until shipment for analysis.
RNA PRE-PROCESSING, LIBRARY PREPARATION, AND SEQUENCING
To increase low-RNA yields, the Nugen Ovation © FFPE RNA-Seq
System (Nugen, CA, USA) was used to amplify cDNA from total
RNA for transcriptome sequencing. Amplification was initiated at
the 3′ end and also randomly throughout the whole transcriptome
in the sample. As described in user’s manual, amplification of both
mRNA and non-polyadenylated transcripts makes the Ovation
RNA-Seq System (Nugen, San Carlos, CA, USA) ideal for amplifi-
cation prior to next generation sequencing (NGS). The amplified
cDNA was quantified using Qubit dsDNA BR Assay 2.0 (Invitro-
gen Life Technologies, Grand Island, NY, USA) and all samples
produced ample cDNA yields (1.26–1.89 ng/µl) for library con-
struction. Then 1µl from each sample was diluted 5× for analysis
by Agilent DNA1000 chip to verify that all profiles obtained fit
NuGen’s expected profile. None of the samples were sonicated
because QC analysis done after the Ovation RNAseq FFPE proto-
col showed that the average fragment sizes (417–466 bp) were in an
acceptable range for library prep. Sequencing libraries for whole
transcriptome analysis were prepared with 2µg of each sample
using Illumina Tru-Seq © Library Preparation Kits (Illumina, San
Diego, CA, USA). Two 7-base index sequences were used to prepare
bar-coded libraries for sample multiplexing. Two indexed libraries
were loaded into each lane of flow cells. Sequencing was performed
using Illumina HiSeqH2000 (Illumina, San Diego, CA, USA) at 50
base pairs, paired end, and 25 million paired reads per sample fol-
lowing the manufacturer’s protocol. Multiplexed single-read runs
were carried out with a total of 107 cycles. The RNA-Seq dataset
has been deposited in the NCBI SRA with accession ID SRP048735.
DATA PRE-PROCESSING AND ALIGNMENT OF SEQUENCED READS
FASTQ sequence files were generated from the raw base-call data
for all 18 samples using CASAVA 1.8 (Illumina, CA, USA), the stan-
dard data processing package from Illumina. De-multiplexing of
sample indices was set with one mismatch tolerance to separate the
two samples within each lane. Quality assessment of raw FASTQ
reads was performed using the FASTQC program, as previously
described (17).
The paired end reads were aligned against the Ensembl
GRCh37.62 B (hg19) reference genome using 150 as the mate
pair means inner distance and the pre-set settings in TopHat
v2.0.6. The alignment quality and distribution of the reads were
estimated using SAMTools v1.18 (Illumina, CA, USA). The refer-
ence genome-guided transcript assembly of the aligned reads was
performed using quartile normalization, bias correction, and the
default assembly settings for Cufflinks v2.1.1. The transcript abun-
dance was calculated by estimating the fragments per kilobase of
exon per million mapped fragments (FPKM), and all expressed
transcripts were binned (0, <1, 1–10, and >10) on the basis of
their abundance (FPKM).
DATA VISUALIZATION AND CLUSTERING ANALYSIS
The similarity of the relative gene transcript abundances (using
Log2 transformed values of FPKM) for each of the 18 samples
were compared using Spearman’s correlation calculation in SAS
and an unsupervised hierarchical clustering analysis in Gene-E, a
visualization tool developed by the Broad Institute (http://www.
broadinstitute.org/cancer/software/GENE-E/). The pairwise com-
parisons of FPKM between normal to LGSIL and LGSIL to HGSIL
in each sample were compared between the tissues from these three
stages and visualized as stacked histograms by genomic location
in each chromosome using Circos plots (18).
DIFFERENTIAL GENE EXPRESSION ANALYSIS
UCSC known genes annotation was used to assess differentially
expressed genes for the pre-cancer stage effect using CuffDiff tools
(19) in two different methods: (1) grouping all six samples by
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their tissue classification and comparing the geometric averages
progressively between normal vs. LGSIL and LGSIL vs. HGSIL;
and (2) comparing the geometric averages progressively within
each individual separately (six pairs for normal to LGSIL and
six pairs for LGSIL to HGSIL) using CuffDiff, and then merg-
ing the results across all individuals. Because of the small sample
size and unique sample type, both methods were assessed to fully
capture the variability in the structured experimental design. To
account and adjust for multiple testing, the FDR q-values were
calculated by CuffDiff from the raw p-values, which are estimated
using beta negative binomial tests of variance in read counts
(19). Transcripts were considered to be differentially expressed
if their expression values (log2) differed by a factor of 1.5 and
FDR< 0.05. For FPKM= 0, zero to positive KPKM was consid-
ered positive infinity and positive KPFM to zero was considered
negative infinity (Tables S3A,B in Supplementary Material). Vol-
cano plots of –log10(p-value) vs. Log2 (FPKM) fold-change were
made to examine these association in each tissue pair within each
individual.
PATHWAY ENRICHMENT ANALYSIS
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) was used
for gene ontology (GO) analysis to identify pathways that were
enriched in all significant gene lists by each of the progression
stage pairs (LGSIL vs. Normal, HGSIL vs. LGSIL) (20). Only genes
that were differentially expressed in at least two participant sample
comparisons (both in direction and significance at FDR q≤ 0.05)
were included in the analysis. Statistical significance was estimated
using the hypergeometric test and GO categories were considered
to be significant if the pathway included at least five genes and
the adjusted p-value of enrichment using a Benjamini–Hochberg
FDR correction was ≤0.05.
RESULTS
The mRNA sequencing of the co-existing spectrum of normal and
pre-cancer LGSIL and HGSIL on the sample block from 6 patients
(18 samples) generated a total 2.4 billion raw reads, ranging from
264 to 470 million reads per person (Figure 2; Table S1 in Sup-
plementary Material). The overall raw read mean quality score
was high (mean Phred Quality Score= 36.76) with 93.5% of bases
above Q30. Among the 2.4 billion high-quality raw reads, 50.1%
of the reads were mapped to the human genome with known gene
annotations. Of the 29,061 genes across 22 autosomal and X chro-
mosomes, 3727 of them had zero FPKM in all samples so 25,334
genes were examined for differential gene expression (Table S2 in
Supplementary Material).
As shown in the unsupervised hierarchical clustering dendo-
gram (Figure S2A in Supplementary Material),most of the samples
from each cervical pre-cancer stage clustered together by sample
and then by stage in our analysis. Sample #111 showed the most
differences within the three stages and sample #115, which clus-
tered all three stages, seemed to be in a different branch. Overall,
more genes were up-regulated during progression from normal to
LGSIL, with samples #115 and #116 having the largest numbers
FIGURE 2 | Overview of the steps involved in the mRNA sequencing analysis of normal (N), LGSIL (L), and HGSIL (H) pre-cancer lesions in six patient
samples (#109, #110, #111, #113, #115, and #116).
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(Figure 2; Table S3A in Supplementary Material). On the other
hand, more genes were down-regulated during progression from
LGSIL to HGSIL, with samples #111 and #115 having the largest
number of genes (Figure 2; Table S3B in Supplementary Material).
Down-regulation of genes is a hallmark signature of advanced pre-
cancer progression to cancer. One patient sample (#115), which
consistently had a larger number of differentially expressed genes
in both progression from normal to LGSIL and LGSIL to HGSIL,
was one of two samples that displayed moderate dysplasia (CIN2).
None of the 25,334 genes were differentially expressed after
stringent statistical correction (FDR p≤ 0.05), using the first
method when the analysis performed was combined for all merged
samples (by pre-cancer stage) (Tables S3A,B in Supplementary
Material). However, three genes (C1orf120, EPGN, and NDRG4)
were differentially expressed (FDR q≤ 0.20) during progres-
sion from normal to LGSIL and six genes (ADH7, AX746562,
CRNN,FABP,SLN, andSPRR3) were differentially expressed (FDR
q≤ 0.20) during progression from LGSIL to HGSIL as listed in
Table 2 (all results in Tables S3A,B in Supplementary Material).
The main analysis using the second method was focused on the
differentially expressed genes (FDR p≤ 0.05) identified by pair-
wise comparison of each sample separately using CuffDiff (Figure
S3 in Supplementary Material). Between 6 patient samples of nor-
mal to LGSIL pairs, there were a total of 211 genes down-regulated
and 429 up-regulated (Figure 3A). Of these, S100A7 and KLK6
were differentially up-regulated in 3 of 6 patient samples (FDR
q≤ 0.05); whereas,CCL18,FLT3, andRORC were down-regulated
and 38 genes were up-regulated in 2 of 6 patients (Figure 3B). In
progression to high-grade pre-cancer (LGSIL to HGSIL), although
there were a total of 187 different genes up-regulated in various
samples, the majority (165) were present in one patient sample
(#115), which displayed moderate dysplasia. Overall, C12orf63,
KRTDAP, SBSN, FABP4, CBLN1 were down-regulated whereas
CTCFL and PLAC8L1 were up-regulated in at least two of six sam-
ples (Table 3). When comparing the progression from LGSIL to
HGSIL in these six patient samples, seven genes were differentially
expressed in at least two samples (Table 3).
Of the 43 differentially expressed genes in at least 2 partici-
pant samples in progression from normal to LGSIL (Table 3), 7
(CLCA2, CRCT1, PKP1, S100A7, PLCH2, SPRR1B, and NADK )
were mapped to chromosome 1 and another 7 (KLK6, CASP14,
CNFN, KLK12, KLK11, KLK10, KLK13) to chromosome 19.
Cytoband location 19q13.3–q13.4 was common for differentially
expressed KLK gene family (KLK12, KLK11, KLK10, and KLK13),
the serine proteases encoded from this Kallikrein gene family have
been implicated in various cancers (21). Of the 7 genes differ-
entially expressed for LGSIL to HGSIL in at least 2/6 individuals
(Table 3), KRTDAP and SBSN were mapped to chromosome 19
with the others mapped to different chromosomes.
With progression from normal to LGSIL, six genes (SPRR1B,
CNFN, TP63, PAX2, SCEL, S100A7 ) were enriched in can-
cer pathways including GO:0030855, epithelial cell differenti-
ation (adj p≤ 7.4 E-3), and GO:0008544, epidermis develop-
ment (adj p= 0.05). Five genes (CNFN, SPRR1B, S100A7, SCEL,
TP63) were enriched in GO:0030216 ~ keratinocyte differentia-
tion (p≤ 1.10E-03) and GO:0009913, epidermal cell differenti-
ation (adj p≤ 1.3E-3). Several other pathways (Figure S4A in
Supplementary Material) were enriched with the clusters of dif-
ferentially expressed genes: GO:0017171, serine hydrolase activity
(5 genes, adj p≤ 1.0E-3), GO:0004252, serine-type endopepti-
dase activity (5 genes, adj p≤ 1.0E-3), GO:0004175, endopeptidase
activity (6 genes, adj p≤ 1.8E-3), GO:0008509 anion transmem-
brane transporter activity (5 genes, adj p≤ 1.8E-3), GO:0070011
peptidase activity, acting on l-amino acid peptides (6 genes,
adj p≤ 1.32E-2), GO:0008233 peptidase activity (6 genes, adj
p≤ 1.51E-2), and GO:0005576, extracellular region (13 genes, adj
p≤ 1.82E-2). No distinct pathways (with more than five genes
and adj p≤ 0.05) were enriched with genes in at least two pairs of
patient samples in progression from LGSIL to HGSIL (Figure S4B
in Supplementary Material).
DISCUSSION
We used next generation RNA-seq methods to study the transcrip-
tomic landscapes of co-existing pre-cancer lesions and understand
the mechanism of pre-cancer progression from normal to LGSIL
and LGSIL to HGSIL in six individuals. To our knowledge, there
have been no published reports of assessment of transcriptomic
expression patterns from co-existing spectrum of neoplasia from a
single sample. In most studies, samples from different individuals
or from different times from the same individual are compared. A
Table 2 | Differentially expressed genes (FDR q ≤0.20) from transcriptome analysis of six samples combined – normal to LGSIL and LGSIL to
HGSIL (Log2 transformed).
Gene Locus Normal LGSIL Fold-change p-Value q-Value
Normal to LGSIL
C1orf120 chr1:182376755-182383948 11.0013 0 −inf 5.00E-05 0.18
EPGN chr4:74979895-75196255 0 3.33617 +inf 5.00E-05 0.18
NDRG4 chr16:58497548-58547522 7.04797 85.1306 3.5944 5.00E-05 0.18
LGSIL to HGSIL
ADH7 chr4:100333417-100356525 2.89046 0 −inf 5.00E-05 0.18
AX746562 chr7:44406738-44408891 0 4.34595 inf 5.00E-05 0.18
CRNN chr1:152381718-152386750 194.411 2.41024 −6.33379 5.00E-05 0.18
FABP4 chr8:82390731-82395473 237.894 15.9085 −3.90245 5.00E-05 0.18
SLN chr11:107578108-107582787 0 25.907 inf 5.00E-05 0.18
SPRR3 chr1:152974222-152976332 350.506 14.4714 −4.59817 5.00E-05 0.18
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FIGURE 3 |The concentric circles represent an heatmap of
−log10(p-value) values of pairwise comparison of the sample’s FPKM
(A) normal to LGSIL and (B) LGSIL to HGSIL in each of six samples. At the
periphery of the heatmap are the genes that report a significant
−log10(p-value) value across at least two samples or more. The concentric
heatmaps are ordered from outmost to innermost in the following sample ID
order: 109, 110, 111, 113, 115, and 116. Each band in the concentric circle
represents a gene and its color scheme corresponds the −log(p-value); RED
bands are values over 1.3, GRAY bands have range between 0.05 and 1.3 and
WHITE (merging with the background of the plot) represents ≤0.05.
Table 3 | Differentially expressed genes in 6 pairs of normal-LGSIL-HGSIL (log2 fold-change >1.5 and FDR p≤0.05).
Common pairs Normal-to-LGSIL (q-value) LGSIL-to-HGSIL (q-value)
3/6 Pairs All up-regulated
KLK6, S100A7
2 up-regulated and 1 down-regulated
ZBTB7C, GALNT5
2/6 Pairs Up-regulated Up-regulated
AK026736, AX748294, BTN1A1, CASP14, CFTR, CHST6, CKMT1A, CLCA2,
CNFN, CRCT1, CWH43, DQ586546, GJB6, HCG22, IFNE, KBTBD11,
KLK10, KLK11, KLK12, KLK13, KRT80, MUC21, NADK, PAX2, PKP1,
PLA2G4F, PLCH2, POLQ, RHOV, SAA2, SCEL, SLC26A11, SLC5A8,
SLC6A14, SLCO1B3, SPRR1B,TFF3,TP63
CTCFL, PLAC8L1
1 up-regulated and 1 down-regulated 1 up-regulated and 1 down-regulated
GABRP, GPR110, IRF6, LY6G6C, MUC4,WDR72 BTK, C9orf122, CD1E, FGB, SLITRK2,WDR49
Down-regulated Down-regulated
CCL18, FLT3, RORC C12orf63, KRTDAP, SBSN, CBLN1, FABP4
major advance in functional genomic investigations is the use of
NGS, RNA-seq with ex vivo-derived genetic material originating
from morphologically distinct cellular subpopulations within tis-
sue. The first application combining LCM and cDNA microarray
technologies to analyze gene expression in breast cancer speci-
mens was reported in 1999 (22). Since then, most investigations of
changes in gene expression associated with the progression stages
in cancer have been targeted for breast cancer, prostate cancer, lung
cancer, and colorectal cancer (23–30). Reports of gene expression
studies of cervical cancer are sparse, specifically for pre-cancer
lesions (31–33).
Using gene expression transcripts clustered by pre-cancer lesion
grades, several genes were either down- or up-regulated during the
progression process in each individual (Figures 3A,B). However,
Frontiers in Oncology | Cancer Genetics November 2014 | Volume 4 | Article 339 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Royse et al. Cervical pre-cancer gene expression
43 genes were differentially expressed (in the same direction and
statistically significant) in the samples from normal to LGSIL and
7 genes were differentially expressed from LGSIL to HGSIL in 2
or more individuals of the 6 participants (Table 3). In particular,
S100A7 and KLK6 genes were differentially expressed during pro-
gression from normal tissue to LGSIL in 3/6 samples and could be
key members of signature networks in cervical pre-cancer progres-
sion. The KLK6 gene was differentially up-regulated in 3/6 LGSIL
samples compared to HGSIL; whereas,KLK10, 11, 12, and 13 were
also up-regulated in 2/6 samples. The KLK gene family is a mem-
ber of the protease clan PA, protease family S1 with subfamily A,
located on chromosome 19q13.3–q13.4. KLK6 along with 10 and
11 and 13 are emerging biomarkers for ovarian and cancer (34).
Moreover, KLK6 has been differentially expressed in breast, uter-
ine, and colon cancers (35–37). The S100A7 gene, also known as
psoriasin, is located within the epidermal differentiation complex
on human chromosome 1q21 (38) and plays an important role
as an immunomodulatory protein in skin (39). Increased S100A7
expression has been reported in several epithelial malignancies,
including head and neck squamous cell carcinoma (HNSCC) and
oral dysplasia (40), which shares many features, including HPV
infection, with cervical SCC, as well as skin, bladder, breast cancer,
and adenocarcinomas of the stomach (41). However, we did not
test for HPV and could not assess the interactions of these genes
with HPV.
Three other genes are also noteworthy, chemokine (C–C motif)
ligand 18 (CCL18) (42), cystic fibrosis transmembrane conduc-
tance regulator (CFTR) (43), and solute carrier family 6 member
14 (SLC6A14), as they have been reported to be up-regulated in
cervical cancer malignancy and in the same direction as in pro-
gression from normal to LGSIL in our study (44). CCL18 is known
to be involved in adaptive immune system and its role in cancer is
not fully known but is best known for inducing metastasis of breast
cancer cells by binding to PITPNM3 (45). CFTR, found in epithe-
lial cells functions as a cAMP-activated ATP-gated anion channel
and SLC6A14 functions as Na+ and Cl− dependent neutral and
basic amino acid transporter, but their roles in cancer are not
known. Of note, two genes ZBTB7C and GALNT5 were differen-
tially expressed in the same direction in two samples but opposite
in the third in normal to LGSIL progression. The pathway analysis
of these genes provided further insight into the expression profil-
ing of genes involved in pre-cancer progression. The functions of
the genes identified in the progression from normal to LGSIL were
enriched in the biological processes and pathways of keratinocyte
differentiation, epidermis development, peptidase activities, and
extracellular region activities.
Inclusion of pre-cancer tissues from the same individual with
respect to time and space is a major strength of this approach
where all internal confounders are controlled for in determin-
ing signature gene expression patterns. However, there might
be residual heterogeneity in samples between patients (Figure
S2 in Supplementary Material); thus, the analysis from progres-
sion within each individual might be more informative than the
combined analysis taking the mean or median values across dif-
ferent stages from different individuals. For instance, four patient
samples had ICD9 code 233.1 (carcinoma in situ) (Table 1) and
three of them (samples #109, #110, and #116) had S100A7 genes
up-regulated and another set (samples #110, #111, and #116) had
KLK6 up-regulated in normal to LGSIL pairs. Samples #113 and
#115 may have differing cellular makeups since their HGSIL were
diagnosed as moderate dysplasia (CIN2) (ICD9 code 622.12).
Microdissection methods create a homogeneous sample, but any
error in procedures can include adjacent heterogeneous tissues.
For example, in samples #109 and #110, HGSIL cells were adja-
cent to normal samples (Table 1) and contaminated samples can
also misclassify the expression patterns. Also, microarray tech-
nologies typically require fresh tissues; however, FFPE tissues have
been regularly used in clinical research. With careful selection of
samples, such as the age of the sample, length, and conditions of
storage (13, 46), gene expression analyses of FFPE tissues have
shown comparable results to frozen tissues (47–49). In addition,
various new technologies have proven that RNA acquired by laser-
capture microdissection from FFPE samples also yields reliable
microarray and NGS data (50). Our use of LCM to separate a het-
erogeneous sample as well as presence of common gene signatures
for cervical pre-cancer lead us to have more confidence in the phe-
notype and therefore results. Utilization of FFPE blocks in such
genomic approaches is innovative as they can provide tremen-
dous resources and opportunities for epidemiological, basic, and
translational studies.
While effective prophylactic vaccines are available (for HPV
types 6, 11, 16, and 18), there is no treatment for infected indi-
viduals and logistic issues of vaccine delivery still exist. Thus,
discovering biomarkers that are associated with the progression
of pre-cancer lesions and cancer are extremely important. We are
cognizant that our study is limited by number of patient sam-
ples and our findings need to be replicated in larger study. Thus,
it is unknown if some of these gene patterns observed might be
rare and specific to individual patients and thus may not be used
as universal biomarker for progression. However, our approach
of using co-existing samples is novel and may enable accurate
aggregate genomic information regarding the potential mecha-
nism or pathway of progression, since all known and unknown
confounding factors are controlled for by internal comparisons.
The identified differentially expressed genes (validated in two or
three samples), specifically S100A7, KLK6, CCL18, CFTR, and
SLC6A14, with reports of involvement in other cancers or novel
ones with potentially related biological pathways, represent targets
for understanding mechanisms of pre-cancer progression.
Since complex processes regulate gene expression, it is very
likely that not all important transcriptome genes were identified
and conversely that some gene expression changes identified in this
study may not later be confirmed, and therefore, the results of this
study should be replicated in larger studies. Additionally, we chose
to only assess differential gene expression in co-existing lesions
although there are other processes and markers of expression
including RNA-splicing and transcript expression that were not
assessed in the analysis. Despite these limitations, we successfully
designed and analyzed a novel application of RNA-Seq technology
to identify and annotate genes and networks that may be present
in cervical co-existing lesions. Future studies can examine other
complexities of the transcriptome using the RNA-seq data includ-
ing splice junctions, fusion, allelic variants including somatic
mutations, and HPV integration that could aggregately either
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explain these differential gene expression patterns or progression
of pre-cancer.
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